Financial Blogger, Contributor, Model Portfolio
Bret Jensen is a Financial Blogger and Contributor at Model Portfolio. He covers a diverse range of topics including finance, trading, and healthcare, with a particular focus on markets, biotech, the Federal Reserve, AI, and the FDA. Bret's insights and analyses have been featured in TheStreet and Seeking Alpha.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Bret Jensen's articles predominantly cover investment analysis in the healthcare, pharmaceutical, and biotechnology sectors. He frequently cites data to support his analysis. To effectively reach out to Bret, provide well-researched insights or expert commentary on companies within the pharmaceutical and biotech industries that are backed by solid data and financial analysis.
Given his focus on stock market coverage within these sectors, pitches should be tailored to appeal to investors seeking detailed financial and industry-specific insights into pharmaceuticals, biotechnology, and medical technology companies. Although Bret doesn't have a specific geographic focus mentioned, it would be beneficial for sources with international perspectives or those impacting global markets to engage him effectively.
This information evolves through artificial intelligence and human feedback. Improve this profile .
A solid covered call trade around a promising oncology name.
Several biotech and biopharma stocks that should prosper in the coming year, particularly one with a leading hepatitis B vaccine.
We take our first look at Tactile Systems Technology, a medical device firm. The stock has fallen due to disappointed Q3 revenue results. Read more details here.
By: Bret Jensen
Viridian Therapeutics, Inc.'s stock soars on positive trial results, analysts bullish on FDA approval in 2026. Read more on VRDN stock prospects.
Tyra Biosciences' shares have dropped sharply after interim data from TYRA-300 showed a superior but not exceptional adverse event profile and tepid duration of response at 90mg.
Let's step back and take stock of the past couple months and see what to watch for the new year -- and what to watch out for.
Vericel Corporation, specializing in cellular therapies for sports medicine and severe burn care, has seen a 40% rise in its stock recently. Read our take on the stock on Seeking Alpha.
By: Bret Jensen
Ardelyx's tenapanor franchise, including Ibsrela and Xphozah, shows strong sales growth, but Xphozah's future is uncertain without Medicare Part D coverage. Read more here.
(833) 317-6278 
